HK Stock Market Move | INNOCARE (09969) rose over 4% in early trading, marking the company's first reversal from losses to profits. The core product, Obeticholic acid, made a significant contribution to the increased income.

INNOCARE (09969) rose more than 4% in the morning session, and as of the release of this article, it is up 3.95% to HK$11.83, with a trading volume of HK$386.91 million. On the news front, INNOCARE previously announced its performance forecast, expecting to achieve revenue of RMB 2.37 billion in 2025, a year-on-year increase of approximately 134%; it is expected that the net profit attributable to owners of the company in 2025 will turn losses into profits for the first time, reaching around RMB 630 million. The core product Osimertinib contributed significantly to the increase in revenue, and after the approval of Tantexi monoclonal antibody in May 2025 was listed, it further enriched the source of income from drugs. The two BD transactions completed during the year are also another important factor leading to the rapid growth in operating income in 2025. It is worth noting that INNOCARE announced that the Phase III clinical trial of its independently developed novel TYK2 inhibitor ICP-488 for the treatment of psoriasis has completed patient enrollment, with a total of 383 patients enrolled. This marks a significant clinical progress in the treatment of psoriasis with ICP-488, offering a new oral treatment option for psoriasis patients. This clinical trial is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of ICP-488 as a monotherapy in adults with severe plaque psoriasis.